The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. - Wikidata - awgldk - TriplyDB

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

http://www.wikidata.org/entity/Q37493951

about

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.Treatment of multiple myeloma bone disease: experimental and clinical data.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis Sotatercept in patients with osteolytic lesions of multiple myeloma.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients.CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Multiple myeloma presenting as acute renal failure The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis.Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspective Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates.The use of zoledronic acid in pediatric cancer patients.Management of hematological malignancies in patients affected by renal failure.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Guidelines for the diagnosis and management of multiple myeloma 2011.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.A current update on osteonecrosis of the jaw and bisphosphonates.

P2860

Q27002668-37DAED48-3CF9-466E-8588-4C58C35462E2 Q27011865-DF0F4360-CA10-4182-A931-8E557DA255B5 Q28730433-980669A1-01FF-4EAB-9666-7DA6C0D3537B Q30501430-53B64476-EBFD-4FED-862A-365DAAD3B98F Q30868833-80078C63-49C6-4B75-84DA-CA76B83CF6ED Q31048683-00CBCF31-0AC4-45E7-88FC-EBCCF0C41D3E Q33865551-7CB5F7B4-B057-4862-8E79-CDE52139AD8B Q33891364-C109FC19-7E2E-46E2-8917-93E86BDB41D6 Q34032539-0C6F9E16-DE47-46F0-991A-9B0ED455D7F8 Q34038854-B8C93E76-7659-4B9F-A9D3-D6C5547648F9 Q34718186-3CCCE1C5-FA80-4F48-B1AB-A3B4E2C6C12B Q35023376-CF1D826D-76CF-46B8-A148-F6E2A8859DA8 Q35035011-FBC9259E-3D43-47BD-B28C-5AAAD3F6B8E6 Q35141814-AAFF9827-9BCA-4714-8384-3ED0D431F3B4 Q35201790-863E8DAA-B644-47B2-95CD-0C24149C8380 Q35266066-144CF5B3-C2D9-4A68-87A7-00BEB25F32C4 Q35422468-BE8D2DAE-4706-43A0-B010-67185EF9FF2D Q35488351-02E883C1-2AFF-40EF-931A-B6C0E8557809 Q35584866-F1B0EAE8-11DF-482B-8DE1-8300C6F80AF1 Q35700723-CF322EA1-A24E-4FE3-9B48-80705C549CBD Q35865686-13E27726-CDA3-4F3B-A2F8-6FF90CAE8812 Q35883011-75A7A5E8-A56A-4E1E-B383-C70556BC592B Q35886257-3157FA31-5224-4204-BA24-F8BA823F3A6A Q36299278-0E2F0A12-0831-4551-811E-9300B3D45A02 Q36568586-43648595-EBC3-4BFA-8BE8-DB16D045EF5B Q36691952-98081F26-B096-4871-AF42-406382D9658A Q36708998-6C024315-9CE6-4424-8F0A-F8F9F3F0553B Q36804951-1C9C9557-5E3B-4E80-98C8-5B7C7C04EC5B Q36929923-B282B52D-FA93-431C-99F8-D5A9B4ABF69E Q37550846-C009319F-97D0-47BA-8F10-EF3B6E956A22 Q37677935-671B3843-4A2E-4C61-9D6E-523F0B9682AE Q37761370-D0724565-14B4-4948-801E-FD95C78CDB7B Q37791005-9D2EA2F1-7996-47E3-9DFC-D9985CFF261C Q37830052-2A4D3676-7AC0-427E-9B5D-A5C8D5B01874 Q37836669-0F7C28A5-F979-4245-B572-9A34D28A74F0 Q37854710-560A5402-5EDE-402A-B3B2-7FED1CE39A23 Q37858523-0EA99EBE-FB49-4394-8482-19B007974EA8 Q37875193-803479E3-E379-48DB-94EE-F9C87C05F06F Q37952851-A55B6134-E9EA-454D-B791-62C4F53E75F0 Q37992647-A4F5C1D6-7414-4E68-AEED-E980BC29AA8D

P2860

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

http://www.wikidata.org/entity/Q37493951

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The use of bisphosphonates in ...... the European Myeloma Network.

@en

The use of bisphosphonates in ...... the European Myeloma Network.

@nl

type

label

The use of bisphosphonates in ...... the European Myeloma Network.

@en

The use of bisphosphonates in ...... the European Myeloma Network.

@nl

prefLabel

The use of bisphosphonates in ...... the European Myeloma Network.

@en

The use of bisphosphonates in ...... the European Myeloma Network.

@nl

P1433

Q37493951-14B3AE99-7655-47CF-99BA-2809E7F47C25

P1476

Q37493951-90FF5CA7-A06C-49EC-9ABF-1A1A35107F03

P2093

Q37493951-012510B0-21CF-47A4-958B-5731E51BA22C

Q37493951-075E23B7-6DEE-4FDE-A396-46A7F266CEF5

Q37493951-14B5A09E-EA99-4BDE-B681-C48CDBA3EB54

Q37493951-32F238D8-547C-4CC3-8902-0523BBCE3EB1

Q37493951-3A143A43-782B-490B-9E86-925482B76B0E

Q37493951-4C08B577-C9CE-4CAA-AFC3-DC2180FF4594

Q37493951-65C7EE05-0B3B-49C0-B195-B8219F6BA8A9

Q37493951-67ACA17B-0248-4A92-817B-A3EA11C0FBA6

Q37493951-777BA069-BC3F-4B73-850B-11F81331AFDD

Q37493951-8690DCD2-03FE-4720-A61D-6850FB4F1ACF

P2860

Q37493951-01CB73CD-C27E-4567-861D-5FBF0E784F60

Q37493951-02C549B7-4BF3-490C-BC0F-16469559E949

Q37493951-04F83654-3CB3-4619-8661-0A7A9C60D463

Q37493951-0A8D4BA9-D9C7-4B92-9F27-AF96991830EF

Q37493951-0E1547C8-A0A7-4ACE-AB25-6466B1EE7910

Q37493951-0FC6AA5D-DC7B-4510-9460-E10D037BABB7

Q37493951-1597A4DE-C48E-41D2-B488-B2DF12338A30

Q37493951-169FBFEF-218C-472B-BFA3-230D03860027

Q37493951-19912A14-3987-4F24-ACFF-C5B35F599EBC

Q37493951-1B2F889D-C80A-4F86-A333-21E779B73FE8

P304

Q37493951-34933A51-27EB-4D16-9D67-2DE0E4B4DBB6

P31

Q37493951-32559B65-FECB-4D14-B6C4-EC42B6427425

P356

Q37493951-51F3C6E1-7BFF-4581-996B-6109FE7A8695

P433

Q37493951-47761BA1-C12C-4D56-B05E-0923DEF1E798

P478

Q37493951-796FB92A-566A-4F58-9888-40AA88D6DB57

P577

Q37493951-89BC07FF-EEF5-4720-8E78-7D85466BF8A5

P5875

Q37493951-DD4ACD8E-A830-44BA-9064-BFB0C6A78D4A

P698

Q37493951-AEE985A6-FF4E-4726-A9AC-D2B355CDCB9D

P356

P1433

Annals of Oncology

P1476

The use of bisphosphonates in ...... the European Myeloma Network.

@en

P2093

A Waage

http://www.w3.org/2001/XMLSchema#string

E Terpos

http://www.w3.org/2001/XMLSchema#string

European Myeloma Network

http://www.w3.org/2001/XMLSchema#string

J Ashcroft

http://www.w3.org/2001/XMLSchema#string

J Bladé

http://www.w3.org/2001/XMLSchema#string

J San Miguel

http://www.w3.org/2001/XMLSchema#string

M Boccadoro

http://www.w3.org/2001/XMLSchema#string

M Cavo

http://www.w3.org/2001/XMLSchema#string

M Delforge

http://www.w3.org/2001/XMLSchema#string

M Macro

http://www.w3.org/2001/XMLSchema#string

P2860

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Complementary and alternative therapies for advanced prostate cancer.

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

RANK ligand and osteoprotegerin in myeloma bone disease.

P304

1303-1317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN796

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26237003

http://www.w3.org/2001/XMLSchema#string

P698

19465418

http://www.w3.org/2001/XMLSchema#string